Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

2024/25 National Genomic Test Directory released in England

01 Feb 2024

In January 2024, NHS England issued an updated version of the National Genomic Test Directory for 2024/2025, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Three documents were published specifying test codes, clinical indications, target genes, the technology by which tests are available, and eligibility criteria for patients: 

  • National Genomic Test Directory for cancer (version 8);
  • National Genomic Test Directory for rare and inherited diseases (version 6);
  • Rare and inherited disease eligibility criteria (version 6).

Six new codes (test-indication combinations) were introduced in the Test Directory for cancer. Some examples of the newly added codes are provided below:

  • M91.84 MYC rearrangement FISH for acute lymphoblastic leukemia;
  • M91.86 t(2;8)(p12;q24) IGK-MYC FISH for acute lymphoblastic leukemia;

Four new codes (test-indication combinations) were introduced for rare and inherited diseases. Some examples of new codes are provided below:

  • R445.1 Common aneuploidy testing NIPT (genome-wide);
  • R448.1 Prenatal testing (small variants/CNVs/STRs, single interval).

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.